<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164110</url>
  </required_header>
  <id_info>
    <org_study_id>UBC301</org_study_id>
    <nct_id>NCT02164110</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children</brief_title>
  <official_title>A Randomized, Single Blind, Multicenter, Therapeutic Confirmatory Study to Assess the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuBiologics Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Universitario IVI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EuBiologics Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy (Immunogenicity) and Safety of Euvichol&#xD;
      in Healthy Adults and Children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, single blind, multicenter, therapeutic confirmatory study to assess the&#xD;
      efficacy (immunogenicity) and safety of Euvichol in healthy adults and children&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>14 days after second doses</time_frame>
    <description>Proportion of subjects exhibiting 4-fold or greater rises in titers of anti-V. cholera O1 antibody, relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>From first shot to 14 days after second dose</time_frame>
    <description>Type and frequency of solicited adverse event type (Day 0 ~ 6), Type and frequency of unsolicited adverse event type (Day 0 ~ Day 28)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>14 days after second doses</time_frame>
    <description>1. Proportion of subjects exhibiting 4-fold or greater rises in titers of anti-V. cholera O139 antibody, relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>From first shot to 14 days after second dose</time_frame>
    <description>1. Change from baseline in vital signs and physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>14 days after second doses</time_frame>
    <description>1. Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) as measured by each anti-V. cholera antibody titer at Week 2 (Visit 3) after the second dose as compared to prior to investigational product dosing (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>14 days after second doses</time_frame>
    <description>1. Change from baseline in laboratory tests (hematologic test, blood chemistry test, urinalysis) to be performed only in subjects who participate in the Pivotal study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3632</enrollment>
  <condition>Prevention Harmful Effects</condition>
  <arm_group>
    <arm_group_label>Euvichol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of doses and intervals: two doses/Weeks 0 and 2&#xD;
Method of administration: oral administration&#xD;
Dose of drug to be administered: 1.5 mL/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shanchol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Number of doses and intervals: two doses/Weeks 0 and 2&#xD;
Method of administration: oral administration&#xD;
Dose of drug to be administered: 1.5 mL/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Euvichol</intervention_name>
    <description>Number of doses and intervals: two doses/Weeks 0 and 2&#xD;
Method of administration: oral administration&#xD;
Dose of drug to be administered: 1.5 mL/dose</description>
    <arm_group_label>Euvichol</arm_group_label>
    <other_name>Oral Cholerae Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shanchol</intervention_name>
    <description>Number of doses and intervals: two doses/Weeks 0 and 2&#xD;
Method of administration: oral administration&#xD;
Dose of drug to be administered: 1.5 mL/dose</description>
    <arm_group_label>Shanchol</arm_group_label>
    <other_name>Oral cholera vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent to study participation voluntarily provided by an individual&#xD;
             or his/her legally acceptable representative.&#xD;
&#xD;
          2. Age of 1 ~ 40 years&#xD;
&#xD;
          3. An individual who can be followed up during the study period and is capable of&#xD;
             complying with the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity reactions to other preventative vaccinations.&#xD;
&#xD;
          2. Immune function disorders including immunodeficiency diseases.&#xD;
&#xD;
          3. An individual thought to have difficulty participating in the study due to severe&#xD;
             chronic diseases, based on the judgment of the investigator.&#xD;
&#xD;
          4. 38â„ƒ or higher body temperature measured prior to investigational product dosing.&#xD;
&#xD;
          5. Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours prior to study&#xD;
             initiation.&#xD;
&#xD;
          6. Diarrhea or administration of antidiarrheal drugs or antibiotics to treat diarrhea&#xD;
             within 1 week prior to study initiation.&#xD;
&#xD;
          7. Other vaccination within 1 week prior to study initiation or planned vaccination&#xD;
             during the study.&#xD;
&#xD;
          8. Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study&#xD;
             initiation.&#xD;
&#xD;
          9. Participation in another clinical trial with investigational product dosing within 1&#xD;
             month prior to study initiation.&#xD;
&#xD;
         10. Pregnant or lactating women.&#xD;
&#xD;
         11. An individual thought to have difficulty participating in the study due to other&#xD;
             reasons, based on the judgment of the investigator&#xD;
&#xD;
         12. Applicable to the Pivotal study only: history of cholera vaccinations or history of&#xD;
             cholera.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto A. Espos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>De La Salle University Hospital Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antonio D. Ligsay, MD</name>
      <address>
        <city>Quezon City</city>
        <zip>4332</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>April 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

